Where are we with postmenopausal hormone therapy in 2005?

References

• MacLennan A. Long-term hormone replacement therapy. Aust Prescriber 2000; 23: 90–92
   Google Scholar
• Posthuma W F, Westendorp R G, Vandenbroucke J P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?. BMJ 1994; 308: 1268–1269
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58–66
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, , Writing Group for the Women's Health Initiative Investigators, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Nelson H D, Humphrey L L, Nygren P, Teutsch S M, Allan J D. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872–881
   PubMed Web of Science ®Google Scholar
• Anderson G, Limacher M, Assaf A, Bassford T, Beresford S A, Black H, Bonds D, Brunner R, Brzyski R, Caan B, , Women's Health Initiative Steering Committee, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• La Vecchia C. Estrogen and combined estrogen–progestogen therapy in the menopause and breast cancer. Breast 2004; 13: 515–518
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Shumaker S, Legault C, Thal L, Rapp S R, Thal L, Lane D S, Fillit H, Stefanick M L, Hendrix S L, Lewis C E, , Women's Health Initiative Memory Study, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–2662
   PubMed Web of Science ®Google Scholar
• Shumaker S, Legault C, Kuller L, Rapp S R, Thal L, Lane D S, Fillit H, Stefanick M L, Hendrix S L, Lewis C E, , Women's Health Initiative Memory Study, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947–2958
   PubMed Web of Science ®Google Scholar
• Maclennan A, Broadbent J, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4: CD002978
   PubMedGoogle Scholar
• Hays J, Ockene J, Brunner R, Kotchen J M, Manson J E, Patterson R E, Aragaki A K, Shumaker S A, Brzyski R G, LaCroix A Z, , Women's Health Initiative Investigators, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839–1854
   PubMed Web of Science ®Google Scholar
• Barnabei V, Grady D, Stovall D, Cauley J A, Lin F, Stuenkel C A, Stefanick M L, Pickar J H. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002; 100: 1209–1218
   PubMed Web of Science ®Google Scholar
• Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87: 16–23
   PubMed Web of Science ®Google Scholar
• Davis S. The effects of tibolone on mood and libido. Menopause 2002; 9: 162–170
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Vicente J, Figueras F, Sanjuan A, Martinez de Osaba M J, Casals E, Pons F, Balasch J, Vanrell J A. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000; 34: 161–168
   PubMed Web of Science ®Google Scholar
• Kokcu A, Cetinkaya M B, Yanik F, Alper T, Malatyalioglu E. The comparison of effects of tibolone and conjugated estrogen–medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000; 36: 75–80
   PubMed Web of Science ®Google Scholar
• Cohen F, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000; 34: 65–73
   PubMed Web of Science ®Google Scholar
• Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996; 276: 1397–1403
   PubMed Web of Science ®Google Scholar
• Berning B, Bennink H, Fauser B. Tibolone and its effects on bone: a review. Climacteric 2001; 4: 120–136
   PubMedGoogle Scholar
• Johnston C C, Jr, Bjarnason N H, Cohen F J, Shah A, Lindsay R, Mitlak B H, Huster W, Draper M W, Harper K D, Heath H, 3rd, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444–3450
   PubMed Web of Science ®Google Scholar
• Maricic M, Adachi J, Sarkar S, Wu W, Wong M, Harper K. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140–1143
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Cauley J, Kulkarni P, Sashegyi A, Cox D, Geiger M. Risk–benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004; 19: 1270–1275
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black D, Mitlak B, Knickerbocker R K, Nickelsen T, Genant H K, Christiansen C, Delmas P D, Zanchetta J R, Stakkestad J, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–645
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199–210
   PubMed Web of Science ®Google Scholar
• Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Mikkola T, Clarkson T. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605–619
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect?. Maturitas 2001; 38: 243–261
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey M, Hawkins M, Carson J, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–980
   PubMed Web of Science ®Google Scholar
• Devor M, Barrett-Connor E, Renvall M, Feigal D J, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275–282
   PubMedGoogle Scholar
• Grodstein F, Stampfer M, Goldhaber S, Manson J E, Colditz G A, Speizer F E, Willett W C, Hennekens C H. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–987
   PubMed Web of Science ®Google Scholar
• Jick H, Derby L, Myers M, Vasilakis C, Newton K. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–983
   PubMed Web of Science ®Google Scholar
• Scarabin P, Oger E, Plu-Bureau G, EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–432
   PubMed Web of Science ®Google Scholar
• Davies G, Huster W, Lu Y, Plouffe L J, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558–565
   PubMed Web of Science ®Google Scholar
• LeBlanc E, Janowsky J, Chan B, Nelson H. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285: 1489–1499
   PubMed Web of Science ®Google Scholar
• Zandi P, Carlson M, Plassman B, Tschanz J T, Welsh-Bohmer K A, Steffens D C, Bastian L A, Mehta K M, Breitner J C, Cache County Study Group. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288: 2123–2129
   PubMed Web of Science ®Google Scholar
• Collins J, Schlesselman J. Perimenopausal use of reproductive hormones effects on breast and endometrial cancer. Obstet Gynecol Clin North Am 2002; 29: 511–525
   PubMedGoogle Scholar
• Shah A, Scheele W, Glant M, Fugere P. Raloxifene HCl is not stimulatory in the endometrium as assessed by the blaustein criteria and an estrogenicity scoring system. Prim Care Update Ob Gyn 1998; 5: 167
   PubMedGoogle Scholar
• Volker W, Coelingh Bennink H, Helmond F. Effects of tibolone on the endometrium. Climacteric 2001; 4: 203–208
   PubMedGoogle Scholar
• Fugere P, Scheele W, Shah A, Strack T, Glant M, Jolly E. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000; 182: 568–574
   PubMedGoogle Scholar
• Huber J, Palacios S, Berglund L, Hanggi W, Sathanandan S M, Christau S, Helmond F. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002; 109: 886–893
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Moscarelli E, Plouffe L, Jr, Sarkar S, Ciaccia A, Cummings S, Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104: 837–844
   PubMed Web of Science ®Google Scholar
• Doren M, Rubig A, Coelingh Bennink H, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999; 6: 299–306
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059
   PubMed Web of Science ®Google Scholar
• Gompel A, Jacob D, de Chambine S, Mimoun M, Decroix Y, Rostene W, Poitout P. Action of SERM and SAS (tibolone) on breast tissue. Contracept Fertil Sex 1999; 27: 368–375
   PubMedGoogle Scholar
• Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman M E, Lo S C, Walls E L, Zeng J. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001; 93: 51–56
   PubMedGoogle Scholar
• Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G, Mol-Arts M, Barkfeldt J, von Schoultz B. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717–722
   PubMed Web of Science ®Google Scholar
• Speroff L. The Million Women Study and breast cancer. Maturitas 2003; 46: 1–6
   PubMedGoogle Scholar
• Wierik E, Hendricks P, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen+progestogen therapies: a UK MediPlus study. Climacteric 2004; 7: 197–209
   PubMedGoogle Scholar
• Phillips L, Langer R. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558–566
   PubMed Web of Science ®Google Scholar